[HTML][HTML] Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

A Bertrand, M Kostine, T Barnetche, ME Truchetet… - BMC medicine, 2015 - Springer
Background Targeting CTLA-4 is a recent strategic approach in cancer control: blocking
CTLA-4 enhances an antitumor immunity by promoting T-cell activation and cytotoxic T …

Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis

B Bannwarth, F Péhourcq, T Schaeverbeke… - Clinical …, 1996 - Springer
Low-dose pulse methotrexate has emerged as one of the most frequently used slow-acting,
symptom-modifying antirheumatic drugs in patients with rheumatoid arthritis (RA) because of …

Methotrexate in rheumatoid arthritis: an update

B Bannwarth, L Labat, Y Moride, T Schaeverbeke - Drugs, 1994 - Springer
Methotrexate has been approved for the treatment of refractory rheumatoid arthritis by
several regulatory agencies, including the Food and Drug Administration. The tendency is …

[HTML][HTML] MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease

PA Juge, JS Lee, E Ebstein, H Furukawa… - … England Journal of …, 2018 - Mass Medical Soc
Background Given the phenotypic similarities between rheumatoid arthritis (RA)–associated
interstitial lung disease (ILD)(hereafter, RA-ILD) and idiopathic pulmonary fibrosis, we …

Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease

C Gabay, B Fautrel, J Rech, F Spertini, E Feist… - Annals of the …, 2018 - ard.bmj.com
Objectives Adult-onset Still's disease (AOSD) is a rare systemic autoinflammatory disease;
its management is largely empirical. This is the first clinical study to determine if interleukin …

Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre …

M Kostine, L Rouxel, T Barnetche, R Veillon… - Annals of the …, 2018 - ard.bmj.com
Objectives To evaluate the prevalence and type of rheumatic immune-related adverse
events (irAEs) in patients receiving immune checkpoint inhibitors (ICIs), as well as the …

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors

M Kostine, A Finckh, CO Bingham, K Visser… - Annals of the …, 2021 - ard.bmj.com
Background Rheumatic and musculoskeletal immune-related adverse events (irAEs) are
observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given …

Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry

X Mariette, F Tubach, H Bagheri, M Bardet… - Annals of the …, 2010 - ard.bmj.com
Objective: To describe cases of lymphoma associated with anti-TNF therapy, identify risk
factors, estimate the incidence and compare the risks for different anti-TNF agents. Methods …

Methotrexate and rheumatoid arthritis associated interstitial lung disease

PA Juge, JS Lee, J Lau… - European …, 2021 - Eur Respiratory Soc
Question addressed by the study Methotrexate (MTX) is a key anchor drug for rheumatoid
arthritis (RA) management. Fibrotic interstitial lung disease (ILD) is a common complication …

[PDF][PDF] OX40 ligand contributes to human lupus pathogenesis by promoting T follicular helper response

C Jacquemin, N Schmitt, C Contin-Bordes, Y Liu… - Immunity, 2015 - cell.com
Increased activity of T follicular helper (Tfh) cells plays a major pathogenic role in systemic
lupus erythematosus (SLE). However, the mechanisms that cause aberrant Tfh cell …